USPTO serial 79199948
DIOSYNTH
Reviewed by CopyMark Law Group
Reg. 5273482Status 708Renewal
- Filing date
- Status date
- Registration date
- Aug 29, 2017
- Examiner
- GILBERT,REBECCA L
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with DIOSYNTH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mainak H. Mehta
Mainak H. Mehta Procopio Cory Hargreaves & Savitch525 B Street, Suite 2200San Diego, CA 92101United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Chemical preparations and substances for manufacturing of pharmaceutical products, namely, chemical preparations and substances for manufacturing pharmaceutical products for veterinary applications; chemical additives for manufacturing medicines; chemicals for manufacturing cosmetics, skin cleansers and medicines; chemical preservatives for pharmaceutical preparations; biochemicals, namely, polypeptides, recombinant proteins, organic peptide substrates and monoclonal antibodies for producing products for genetic pharmacology ] | SECTION 71 - CANCELLED | — |
| 005 | [ Medicines and pharmaceutical products, including medicines and pharmaceutical products for veterinary use, namely, medicines and pharmaceutical preparations for the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, urological, urogenital disorders and, gastrointestinal disorders, musculoskeletal disorders, allergies, diabetes, hypertension, erectile dysfunction, sexual dysfunction, stroke, cancer, migraines, pain, obesity, inflammation and inflammatory disease, respiratory and infectious diseases, immunological, bacterial, viral and fungal disorders, mental illness, depression, psychosis, bone and mineral diseases, infertility, menopausal complaints, hormone deficiencies, and sleep disorders; pharmaceutical preparations, namely, preparations to lower cholesterol, smoking cessation preparations, tissue and skin repair preparations, dermatological preparations, and gynecological preparations, contraceptives, muscle relaxants, muscle relaxant antagonists; biotechnological preparations for medical use, namely use in gene therapy; biochemicals, namely, biochemical preparations for medical use, namely use in gene therapy; genetic material, namely, genetically engineered tissue, for transplant purposes for genetic cell therapy ] | SECTION 71 - CANCELLED | — |
| 040 | Custom manufacture of pharmaceuticals | ACTIVE | — |
| 042 | Services of biotechnical, chemical and pharmacological laboratories, namely, scientific and technological research relating to the production of chemicals and biotechnological products for use in preparing pharmaceutical and veterinary preparations; scientific and technological research relating to the production of chemicals and biotechnological products for use in preparing pharmaceutical and veterinary preparations, and scientific consultation related thereto; scientific research, namely, carrying out early evaluations in the field of new medicines; development of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation and research in the field of new product development in the pharmaceutical and health care industries; scientific analysis and research, namely, evaluation of pharmaceutical products; research and development in the pharmaceutical field; scientific research and development with regard to medicines; product development, namely, preparation of pharmaceutical test products; advisory services relating to scientific research, development and analyses of medicines; development of new technologies in the biotechnology sector; providing information with regard to scientific research in the field of biochemistry and biotechnology; scientific research, including in the medical sector | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by FUJIFILM Corporation
- Other trademarks owned by FUJIFILM Corporation
- Other trademarks owned by FUJIFILM Corporation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named DIOSYNTH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 15, 2026 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Dec 8, 2025 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Dec 8, 2025 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Oct 9, 2025 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Jun 30, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Oct 31, 2024 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Oct 31, 2024 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Oct 12, 2024 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| May 16, 2024 | PR75 | POST REGISTRATION ACTION MAILED - SEC. 71 & 15 | — |
| Apr 22, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Aug 22, 2023 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Jan 13, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 29, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 6, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 13, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 13, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 29, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 29, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 13, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 13, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 24, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 2, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 25, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 24, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 24, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 18, 2017 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 18, 2017 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 18, 2017 | RFNP | REFUSAL PROCESSED BY IB | — |
| Jan 24, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 24, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 21, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 19, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 18, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 17, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 17, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 13, 2017 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jan 5, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |